Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Simvastatin in patients with progressive multiple sclerosis--Authors' reply.
Features of Virchow-Robin spaces in newly diagnosed multiple sclerosis patients.
Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin.
Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab.
Cigarette smoking and associated risk of multiple sclerosis in the Iranian population.
Mast cells on the mind: new insights and opportunities.
Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
Sulfocerebrosides upregulate liposome uptake in human astrocytes without inducing a proinflammatory response.
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
A pain-mediated neural signal induces relapse in murine autoimmune encephalomyelitis, a multiple sclerosis model.
Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis.
Future directions of multiple sclerosis rehabilitation research.
Diagnosis of atypical forms of chronic inflammatory demyelinating polyradiculoneuropathy: a practical overview based on some case studies.
An adverse lipid profile is associated with disability and progression in disability, in people with MS.
Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis.
Multiple sclerosis risk loci correlate with cervical cord atrophy and may explain the course of disability.
Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination.
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
Simvastatin Treatment of Patients With Acute Optic Neuritis
Promotion of experimental autoimmune encephalomyelitis upon neutrophil granulocytes' stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP) peptide.
Fertility treatment in spinal cord injury and other neurologic disease.
Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1.
The association of -475 and -631 interleukin-2 gene polymorphism with multiple sclerosis in Iranian patients.
Impaired toll-like receptor 8 signaling in multiple sclerosis.
Subclinical Optic Neuritis in Neuromyelitis Optica.
Pages
« first
‹ previous
…
341
342
343
344
345
346
347
348
349
…
next ›
last »